Genovis AB (publ.) (FRA:5GV)

Market Cap	135.76M +1.9%
Revenue (ttm)	10.64M -10.3%
Net Income	1.92M -24.1%
EPS	0.03 -24.3%
Shares Out	n/a
PE Ratio	70.85
Forward PE	51.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	2.025
Previous Close	2.075
Day's Range	2.025 - 2.025
52-Week Range	1.526 - 2.580
Beta	n/a
RSI	58.11
Earnings Date	Feb 12, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 36
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5GV

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.

Financial numbers in SEK